Please assess the completion status of the following clinical trial:

Trial Title: Guided Biopsy for Mapping Prostate Cancer

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: DIAGNOSTIC
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Patients must have histologically confirmed diagnosis of prostate cancer~* Patients must have elected to undergo radical prostatectomy using an open, laparoscopic or robotic approach~* Patients must be at least 18 years of age and able to provide written informed consent.~* No history of radiotherapy, chemotherapy or hormone therapy within 6 months of surgery~* Primary tumor must be amenable to surgical removal for curative intent~* Patients must have ECOG-performance status 0 or 1 (appendix II)~* Patients must have no history of rectal or anal disease.~* Patients must have adequate organ function as defined by the following criteria:~  * Serum aspartate transaminase (AST; serum glutamic oxaloacetic transaminase \[SGOT\]) and serum alanine transaminase (ALT; serum glutamic pyruvic transaminase \[SGPT\])≤2.5x local laboratory upper limit of normal (ULN), or AST and ALT ≤5x ULN if liver function abnormalities are due to underlying malignancy~ * Total serum bilirubin ≤1.5 x ULN~ * Absolute neutrophil count(ANC)≥1,500/microL~ * Platelets≥lOO,OOO/microL~ * Hemoglobin≥9.0 g/dL~ * Serum calcium≤10.2mg/dL (correct for low albumin if necessary; calcium + (normal albumin - serum albumin)x 0.8)~ * Patients must have serum creatinine\<2 mg/dL or serum creatinine clearance (CrCl)\>40ml/min(CrCl= Wt(kg)x(140-age)\*/72xCr. level,\*female x 0.85)~Inclusion of minorities:~* Members of all races and ethnic groups are eligible for this trial. Women and children are not eligible since prostate cancer is not diagnosed in these groups.

- Gender: MALE
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Prostate cancer (Type: EXPERIMENTAL): A total of 30 patients diagnosed with prostate cancer who have elected to undergo radical prostatectomy are enrolled over a six year period.

Based on this trial design, predict the completion outcome and termination type (if applicable).